Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index; 2 of the 13 sources its claims cite were checked for support.

Reply to “Comment on Neiser et al. Assessment of Dextran Antigenicity of Intravenous Iron Preparations with Enzyme-Linked Immunosorbent Assay (ELISA). Int. J. Mol. Sci. 2016, 17, 1185.”

Open access
Burckhardt, Susanna · 2017 · International Journal of Molecular Sciences

Abstract

Thank you providing the opportunity to reply to the Comment on our recent paper.[...]

Overview

CoChat Summary

TL;DR

Burckhardt replies to Strom and Andreasen's Comment on Neiser et al. (2016), arguing that the ELISA study was never intended to be extrapolated to the clinical setting and defending its use of a new antibody and blinded samples. The reply also contends that recent reports of higher hypersensitivity rates with dextran-based intravenous iron support the value of such in vitro data.

Key findings

  • The 2016 experiments were triggered by earlier criticism of the 2011 immunodiffusion work; they used a new antibody (produced by GenScript) and a different technique (ELISA), with blinded samples run by GenScript to avoid bias.
  • The author states that neither Neiser et al. [1] nor prior publications [3,8] made any claim about the clinical relevance of the experiments, and that the mechanism of intravenous iron-induced hypersensitivity reactions "has not been elucidated yet."
  • The reply cites recent studies [9–12] concluding that hypersensitivity reaction frequency is higher with dextran-based intravenous iron preparations (including newer ones) than with non-dextran products, noting these disagree with the paper cited by Strom and Andreasen [6].
  • The data are said to demonstrate that Isomaltoside 1000 reacts with anti-dextran antibodies when bound to a polynuclear iron core, contrary to Crichton et al.'s speculation that Dextran 1 (not Isomaltoside 1000) does so; the author argues this is important for designing new intravenous iron preparations.

Methods

  • This is a reply letter, not a primary research report; it presents no new experimental data or analyses of its own.
  • It describes the design of the original study under discussion: ELISA with a new anti-dextran antibody and blinded samples, chosen to address prior methodological criticism of the reverse single radial immunodiffusion assay.

Limitations

  • Stated in the paper: the mechanism(s) of intravenous iron-induced hypersensitivity reactions remain unelucidated and more studies are needed; the low incidence of these reactions and lack of understanding of their triggers are noted as reasons any additional data are valuable.
  • Evident from the text: as a reply to a Comment, the piece offers argumentation and references rather than new experiments, so its claims rest on the original 2016 study and cited literature; the author also notes the study was not designed to be extrapolated to the clinical setting.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/ijms18010122

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

0 Valid · 2 Not valid · 4 Not checked · 4 Own results and interpretations

11 references still to check

A free account verifies the references that are still open.

Verify all 11 references — free account
  • Probably not a substantial claim. 4
  • It may state two separate claims as one. 1

Create a free account to see these claims.

Citations

Cites

Show all 12 references

Research works printed but not linked: 1

  1. Ring, 2012, Letter to the Editor on the article “Assessment of dextran antigenicity of intravenous iron products by an immunodiffusion assay”, Port. J. Nephrol. Hypertens., 26, 308

Cited by

Still being checked.

Metadata

Authors
Burckhardt, S.
Affiliations
Vifor Pharma (Switzerland) (CH)
Corresponding author
Burckhardt, Susanna
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2017-01-10
Volume
18
Issue
1
Pages
122
ISSN
1422-0067 (ISSN-L)
OpenAlex
W2571170834
Cited by
0
References
12
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
  • Health Sciences › Medicine › Pharmacology (medical) › Drug-Induced Adverse Reactions
  • Health Sciences › Medicine › Hematology › Blood transfusion and management
Keywords
iron dextran, ELISA, drug safety assessment
MeSH terms
Dextrans, Enzyme-Linked Immunosorbent Assay, Humans, Iron, Administration, Intravenous

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-01, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-01 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Reply to “Comment on Neiser et al. Assessment of Dextran Antigenicity of Intravenous Iron Preparations with Enzyme-Linked Immunosorbent Assay (ELISA). Int. J. Mol. Sci. 2016, 17, 1185.”. https://app.cochat.ai/papers/10.3390/ijms18010122
The paper
Burckhardt, S. (2017). Reply to “Comment on Neiser et al. Assessment of Dextran Antigenicity of Intravenous Iron Preparations with Enzyme-Linked Immunosorbent Assay (ELISA). Int. J. Mol. Sci. 2016, 17, 1185.”. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms18010122

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.